EA200601660A1 - Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами - Google Patents

Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами

Info

Publication number
EA200601660A1
EA200601660A1 EA200601660A EA200601660A EA200601660A1 EA 200601660 A1 EA200601660 A1 EA 200601660A1 EA 200601660 A EA200601660 A EA 200601660A EA 200601660 A EA200601660 A EA 200601660A EA 200601660 A1 EA200601660 A1 EA 200601660A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
diabetes
relates
piperasines
arylipiperidines
Prior art date
Application number
EA200601660A
Other languages
English (en)
Other versions
EA009455B1 (ru
Inventor
Ливен Мерпул
Лео Якобус Йозеф Бакс
Либуше Яроскова
Петер Вальтер Мария Рувенс
Луи Йозеф Элизабет Ван Дер Векен
Марсель Вьейевуа
Йоаннес Теодорус Мария Линдерс
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200601660A1 publication Critical patent/EA200601660A1/ru
Publication of EA009455B1 publication Critical patent/EA009455B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Настоящее изобретение относится к новым арилпиперидиновым или пиперазиновым производным, замещенным определенными 5-членными гетероциклами, обладающим ингибирующей активностью в отношении секреции апоВ/МТР и сопутствующей активностью в отношении снижения уровня липидов. Кроме того, изобретение относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения, а также применению указанных соединений в качестве лекарственного средства для лечения гиперлипидемии, ожирения и диабета типа II (формула (I)). Также изобретение относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения, а также применению указанных соединений в качестве лекарственного средства для лечения атеросклероза, панкреатита, ожирения, гипертриглицеридемии, гиперхолестеринемии, гиперлипидемии, диабета или диабета типа II.
EA200601660A 2004-03-10 2005-03-07 Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами EA009455B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04075771 2004-03-10
PCT/EP2005/051010 WO2005085226A1 (en) 2004-03-10 2005-03-07 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles

Publications (2)

Publication Number Publication Date
EA200601660A1 true EA200601660A1 (ru) 2006-12-29
EA009455B1 EA009455B1 (ru) 2007-12-28

Family

ID=34928108

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601660A EA009455B1 (ru) 2004-03-10 2005-03-07 Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами

Country Status (27)

Country Link
US (2) US7504400B2 (ru)
EP (1) EP1751131B1 (ru)
JP (1) JP4846709B2 (ru)
KR (1) KR101171211B1 (ru)
CN (1) CN1930143B (ru)
AR (1) AR048316A1 (ru)
AT (1) ATE414698T1 (ru)
AU (1) AU2005219580B2 (ru)
BR (1) BRPI0508514A (ru)
CA (1) CA2558506C (ru)
DK (1) DK1751131T3 (ru)
EA (1) EA009455B1 (ru)
ES (1) ES2317206T3 (ru)
HK (1) HK1103582A1 (ru)
IL (1) IL177939A (ru)
JO (1) JO2537B1 (ru)
MX (1) MXPA06010253A (ru)
MY (1) MY142521A (ru)
NZ (1) NZ548817A (ru)
PA (1) PA8625401A1 (ru)
PL (1) PL1751131T3 (ru)
PT (1) PT1751131E (ru)
SI (1) SI1751131T1 (ru)
TW (1) TWI353984B (ru)
UA (1) UA85215C2 (ru)
WO (1) WO2005085226A1 (ru)
ZA (1) ZA200607542B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CN101663262B (zh) * 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2009079593A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
SI2242759T1 (sl) 2008-02-06 2013-01-31 Astrazeneca Ab Spojine
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
PT2470552E (pt) 2009-08-26 2014-01-30 Sanofi Sa Novos hidratos de fluoroglicósido heteroaromáticos cristalinos, fármacos compreendendo estes compostos e sua utilização
CA2798002C (en) * 2010-05-19 2019-12-03 Sandoz Ag Process for the preparation of chiral triazolones
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
RU2686323C2 (ru) 2013-03-13 2019-04-25 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
KR101720937B1 (ko) * 2013-04-25 2017-03-29 주식회사유한양행 신규의 트라이아졸론 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
CN105722830B (zh) 2013-06-20 2019-06-04 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物
CN105473558B (zh) 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
WO2015016195A1 (ja) 2013-07-29 2015-02-05 協和発酵キリン株式会社 Ｗｎｔシグナル阻害剤
US10301318B2 (en) * 2014-06-25 2019-05-28 The General Hospital Corporation Neuroactive compounds and methods of using the same
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
EP3464262B1 (en) * 2016-05-27 2020-02-26 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
CN109476646A (zh) 2016-07-12 2019-03-15 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
WO2018139436A1 (ja) 2017-01-24 2018-08-02 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2022187206A1 (en) * 2021-03-01 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof
GB202216960D0 (en) * 2022-11-14 2022-12-28 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents

Also Published As

Publication number Publication date
CA2558506A1 (en) 2005-09-15
CN1930143A (zh) 2007-03-14
AR048316A1 (es) 2006-04-19
PL1751131T3 (pl) 2009-04-30
EA009455B1 (ru) 2007-12-28
NZ548817A (en) 2009-04-30
WO2005085226A1 (en) 2005-09-15
AU2005219580B2 (en) 2010-07-08
JO2537B1 (en) 2010-09-05
TWI353984B (en) 2011-12-11
US20070191383A1 (en) 2007-08-16
PT1751131E (pt) 2009-02-13
ATE414698T1 (de) 2008-12-15
ZA200607542B (en) 2008-05-28
AU2005219580A1 (en) 2005-09-15
HK1103582A1 (en) 2007-12-21
PA8625401A1 (es) 2005-09-28
KR20070014121A (ko) 2007-01-31
JP2007527897A (ja) 2007-10-04
BRPI0508514A (pt) 2007-08-14
US7816360B2 (en) 2010-10-19
EP1751131A1 (en) 2007-02-14
MY142521A (en) 2010-12-15
MXPA06010253A (es) 2007-02-16
JP4846709B2 (ja) 2011-12-28
SI1751131T1 (sl) 2009-04-30
TW200540169A (en) 2005-12-16
US7504400B2 (en) 2009-03-17
IL177939A0 (en) 2006-12-31
UA85215C2 (ru) 2009-01-12
CA2558506C (en) 2012-09-11
KR101171211B1 (ko) 2012-08-07
IL177939A (en) 2011-08-31
DK1751131T3 (da) 2009-03-16
US20100004263A1 (en) 2010-01-07
EP1751131B1 (en) 2008-11-19
CN1930143B (zh) 2012-04-04
ES2317206T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
EA200601239A1 (ru) Замещённые хинолиновые соединения
BRPI0410630A (pt) antagonista de nk1
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200870521A1 (ru) Замещенные спироциклические антагонисты cgrp-рецепторов
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
NO20060718L (no) Substituerte tiofoner og deres anvendelse
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
HK1137011A1 (en) Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
EA200801137A1 (ru) Соединения для ингибирования апоптоза
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
NO20064601L (no) Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
ATE327749T1 (de) Hypoestoxide, derivate und agonisten davon zur verwendung bei der behandlung und prophylaxe von hyperlipidämie
JO2529B1 (en) Ariel pybradine is a substitute for phenyl carboxymides

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU